ORLANDO, FL – BeneCard PBF earned the highest client satisfaction rating in 39 of the 42 categories in the 2015 Pharmacy Benefit Management Institute (PBMI) PBM Customer Satisfaction Survey. The survey, conducted annually, compares all of the top PBMs in the country.
“This is a great validation of how the BeneCard PBF model can provide clients with more of what they want,” said Ken Ullman, chairman of the board of directors. “It’s also a great message to the marketplace that BeneCard PBF is now a tested and proven alternative.”
BeneCard PBF offers full pass-through pricing and transparency with a “High Touch” service model. Two of the categories in which BeneCard PBF led the industry were “delivering promised savings” and “delivering promised services.” This is now the second year in a row that BeneCard PBF has been rated “most likely to be recommended” in the PBMI survey.
Michael Perry, president of BeneCard PBF said, “It’s our employees who deserve the accolades. The BeneCard PBF team always puts members and clients first. When you do that and focus on your clients’ goals, there is no limit to what can be achieved.”
As part of its mission to study best practices and drive process improvement, PBMI has conducted the annual pharmacy benefit manager (PBM) customer satisfaction survey for nearly two decades. The PBMI survey has since become the trusted benchmark of the PBM marketplace. The PBMI survey was completed in January 2015 by 421 U.S. plan sponsors, representing more than 96.6 million members. BeneCard PBF was compared with other pharmacy benefit managers with 20 million or fewer members. In an unparalleled performance, BeneCard PBF received the highest scores in the 39 categories of any PBM, regardless of size.
“The PBMI results demonstrate the direct link between transparency, delivery of promised savings, and client satisfaction,” observed Robert Cascarano, executive vice president of BeneCard PBF. “We are proud to serve each of our clients and appreciate their support.”
About BeneCard PBF
BeneCard PBF has locations in Florida, Pennsylvania and New Jersey focused on administering fixed-rate and self-funded prescription benefit programs. BeneCard PBF’s goal is to improve patient health by aligning the mutual interests of payers, pharmacies and providers.
The Pharmacy Benefit Management Institute (PBMI) provides research and education to help health care benefit executives work with pharmacy benefit managers to improve the design and management of drug benefit programs.
On January 30, 2015, the U.S. Food and Drug Administration (FDA) approved a new formulation for all strengths of Zohydro ER, the single-agent, extended-release hydrocodone product, which is a schedule II controlled substance. Zohydro ER, manufactured by Zogenix, is indicated to treat severe chronic pain that needs continuous treatment and that has not been relieved by previous therapy options.
The new form is considered ‘abuse resistant’ and it is made with a proprietary technology called BeadTek. BeadTek creates thick, sticky goo if the capsules are opened or crushed and the specifies abuse resistance, however, Zogenix, is planning to provide the FDA with results of studies showing that the new formulation is difficult to abuse.
The first FDA approved version of Zohydro ER was approved in October 2013 without any abuse deterrents and will be phased out and replaced with the new form during the second quarter of 2015.
Par Pharmaceutical Companies, Inc. announced that the US Food and Drug Administration (FDA) approved the AB-rated generic version of Exforge (amlodipine/valsartan). Brand Exforge is manufactured by Novartis. Exforge is used for the treatment of high blood pressure.
The generic of Exforge will be available in all current dosage strengths including 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320 mg tablets. Par Pharmaceutical Companies, Inc. was also granted 180 days exclusivity before any other new generics can be approved by the FDA. According to IMS health, Exforge saw annual sales of approximately $422 million.
On January 12, 2015, the generic equivalent to Clobex Spray, 0.05% was launched by Perrigo Company. The brand name Clobex Spray, 0.05% is manufactured by Galderma Laboratories.
Clobex Spray is indicated for the topical treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area in adults.
Generics to Clobex Lotion and Shampoo are already available on the market.